Drug Development in Inflammatory Bowel Diseases: What Is Next?

Posted by Michael Jannicelli | Jun 24, 2026 | Uncategorized | 0 |

This review aims to explore new and emerging therapies for IBD, focusing on the most recent phase II–III studies of novel drugs. These include interleukin (IL) 12/23 inhibitors, TL1A inhibitors, selective up-regulators of miR-124 (e.g., obefazimod), activators of NLRX1 (e.g., NX-13), RIPK inhibitors, and sphingosine-1-phosphate (S1P) receptor modulators (immunomodulators).

A 2025 review in Pharmaceuticals outlines the emerging therapeutic landscape for Crohn’s Disease and…

Michael Jannicelli

Michael Jannicelli - "A PROVEN BUSINESS FIRESTARTER & BRANDING GENIUS" a true natural born Trendsetter. • Created over 100 products under 3 brands, sold in 30+ countries worldwide and influencing youth across the globe. • Featured in Forbes magazine +over 100 print publications, television talk shows, major motion pictures and national radio stations. • Co-founder and VP of Bliss beverage USA and President/co-founder of Socko International - fastest growing privately held beverage company in US (Forbes) with Hogan Energy & Raw Energy WWE. • Co-founder of Throwdown Industries (2003) - leading brand in multibillion dollar Impact/Action Sports Market (products designed for superior MN • Diagnosed with auto-immune diseases aged 13; using his experience to help others and promote a positive message while developing edgy products to benefit people with chronic illness.